Company Overview and News

58
ASX advances despite resource stocks falling on US-China tensions

2018-06-18 theage.com.au
The Australian sharemarket recorded another positive session despite ongoing trade tensions between the US and China rattling resource stocks.
ASXFF WOPEF RIO BLT RIO MS.PRE MS.PRF MS.PRG MS.PRA OISHF AGO RTPPF ASXFY RTNTF MS OSH OISHY BHPBF AGODY WPL WOPEY MS.PRI BHP RIO MS.PRK ATLGF BBL BHP BHPLF

58
ASX advances despite resource stocks falling on US-China tensions

2018-06-18 smh.com.au
The Australian sharemarket recorded another positive session despite ongoing trade tensions between the US and China rattling resource stocks.
ASXFF WOPEF RIO BLT RIO MS.PRE MS.PRF MS.PRG MS.PRA OISHF AGO RTPPF ASXFY RTNTF MS OSH OISHY BHPBF AGODY WPL WOPEY MS.PRI BHP RIO MS.PRK ATLGF BBL BHP BHPLF

50
RPT-FOCUS-Pipe dream? Chevron, Woodside vie to shape Australia's LNG sector

2018-06-17 reuters
MELBOURNE, June 15 (Reuters) - After spending a decade and billions of dollars developing Australia’s vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

50
Pipe Dream? Chevron, Woodside Vie to Shape Australia's LNG Sector

2018-06-15 rigzone
MELBOURNE, June 15 (Reuters) - After spending a decade and billions of dollars developing Australia's vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

50
Pipe dream? Chevron, Woodside vie to shape Australia's LNG sector

2018-06-15 channelnewsasia
MELBOURNE: After spending a decade and billions of dollars developing Australia's vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

22
Chevron Starts Second Production Unit at Wheatstone LNG in Australia

2018-06-15 rigzone
MELBOURNE, June 15 (Reuters) - Chevron Corp has started producing liquefied natural gas (LNG) at the second unit of its $34 billion Wheatstone development, marking the completion of its two megaprojects in Australia after cost-blowouts and delays.
WOPEF RDS.B RDS.A CVX KYSEY RYDBF RDSB RDSA RYDAF WPL WOPEY

39
Rio Tinto hires CFO from Danish shipper Maersk

2018-06-12 channelnewsasia
Major miner Rio Tinto named Jacob Stausholm, formerly CFO of Danish shipping company A.P. Moller-Maersk, to replace outgoing financial boss Chris Lynch when he retires in September, the Anglo-Australian mining company said on Tuesday.
WOPEF RIO RDS.B RDS.A RIO RDSB RDSA WPL WOPEY RTPPF RIO RYDBF RTNTF LNSTY RYDAF

39
Rio Tinto hires CFO from Danish shipper Maersk

2018-06-12 reuters
(Reuters) - Major miner Rio Tinto (RIO.L) (RIO.AX) named Jacob Stausholm, formerly CFO of Danish shipping company A.P. Moller-Maersk, to replace outgoing financial boss Chris Lynch when he retires in September, the Anglo-Australian mining company said on Tuesday.
WOPEF RIO RDS.B RDS.A RIO RDSB RDSA WPL WOPEY RTPPF RIO RYDBF RTNTF LNSTY RYDAF

38
Rio Tinto appoints chief financial officer

2018-06-12 australianmining.com.au
Stausholm, who recently stepped down as group chief financial officer of A.P. Moller – Maersk, will take over as CFO in September, while also starting as an executive director.
WOPEF RIO RDS.B RDS.A RIO RDSB RDSA WPL WOPEY RTPPF RIO RYDBF RTNTF RYDAF

14
TechnipFMC Wins Pluto Upgrade Award From Woodside Petroleum

2018-06-06 zacks
TechnipFMC plc (FTI - Free Report) was recently awarded a contract from the Australian operator, Woodside Petroleum Limited, for platform upgrade of the Pluto project. Per the contract, TechnipFMC will carry out engineering, procurement, construction, installation and commissioning of the Pluto water handling module. The module will be installed on the Pluto Alpha Gas Production Platform, and provide water separation and treatment facilities, along with upgraded power-generation units.
WOPEF NR AROC CKH WPL WOPEY

14
ASX slides despite growing optimism on economy

2018-06-05 theage.com.au
Australian shares shrugged off upbeat economic data to slide on Tuesday as miners and energy names tumbled, while Mortgage Choice shares plunged following a media investigation.
WOPEF MS.PRE MS.PRF MS.PRG IGO IIDDY MS.PRA RFG WPL OGFGY WOPEY MS.PRI MS.PRK RFGPF MOC MS OGFGF WNARF WSA ORG

14
ASX slides despite growing optimism on economy

2018-06-05 smh.com.au
Australian shares shrugged off upbeat economic data to slide on Tuesday as miners and energy names tumbled, while Mortgage Choice shares plunged following a media investigation.
WOPEF MS.PRE MS.PRF MS.PRG IGO IIDDY MS.PRA RFG WPL OGFGY WOPEY MS.PRI MS.PRK RFGPF MOC MS OGFGF WNARF WSA ORG

1
Govt backs controversial Fifo camp

2018-06-01 businessnews.com.au
The state government has backed plans for a 700-bed workers camp at Karratha, despite opposition from the local community, after Woodside Petroleum launched a web site that is meant to boost local employment.
WOPEF WPL WOPEY

1
Most of Asia drifts lower; oil prices and Italian politics in spotlight

2018-05-29 cnbc
Most major markets in Asia traded slightly lower on Tuesday, with Italian politics and the slide in oil prices in the spotlight overnight.
WOPEF WPL WOPEY

32
ASX falls on retreating oil prices

2018-05-28 theage.com.au
The Australian sharemarket fell on Monday, led lower by resource stocks as oil and base metal prices retreated.
WOPEF BLT BHPBF TPPTY TPM WPL BCHEY WOPEY BEPTF BPT TPGTF BHP BBL BHP IOF BHPLF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...